• Issue

    Respirology: Volume 24, Issue 11

    1033-1116
    November 2019

ISSUE INFORMATION

Free Access

Issue Information

  • Pages: 1033-1036
  • First Published: 10 October 2019

ORIGINAL ARTICLES

Asthma and Allergy

Quantitative assessment of airway remodelling and response to allergen in asthma

  • Pages: 1073-1080
  • First Published: 07 March 2019
Quantitative assessment of airway remodelling and response to allergen in asthma

Endobronchial optical coherence tomography is used to investigate the microstructural features of airway in allergic individuals with and without asthma, before and after allergen challenge. Quantification of these features reveals significant differences between the asthmatic and non-asthmatic airways both at baseline and in response to allergen.

See related Editorial

COPD

Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross-over trial

  • Pages: 1081-1087
  • First Published: 13 May 2019
Nasal high-flow therapy compared with non-invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross-over trial

Non-invasive ventilation (NIV) reduces transcutaneous partial pressure of carbon dioxide (PtCO2) more than nasal high-flow (NHF) therapy in hypercapnic COPD, but NHF is better tolerated.

See related Editorial

Nasal high flow does not improve exercise tolerance in COPD patients recovering from acute exacerbation: A randomized crossover study

  • Pages: 1088-1094
  • First Published: 06 August 2019
Nasal high flow does not improve exercise tolerance in COPD patients recovering from acute exacerbation: A randomized crossover study

The addition of nasal high flow during high-intensity exercise does not improve endurance in patients with chronic obstructive pulmonary disease participating in pulmonary rehabilitation following exacerbation.

See related Editorial

Pulmonary Vascular Disease

BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo

  • Pages: 1095-1103
  • First Published: 12 April 2019
BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo

Pulmonary arterial hypertension (PAH) is causally linked to reduced bone morphogenetic protein receptor type 2 (BMPR2) expression. Endothelial progenitor cells engineered to overexpress BMPR2 are therapeutic in the rat monocrotaline PAH model, despite short retention time in the lungs. This approach may have clinical potential.

See related Editorial

Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension

  • Pages: 1104-1110
  • First Published: 08 April 2019

Osteopontin (OPN), a pleiotropic cytokine, was identified among the top five upregulated genes in the lung explants from patients with Group I pulmonary arterial hypertension, compared to normal controls. Its expression correlated strongly to haemodynamic severity. Ingenuity pathway analysis showed the involvement of OPN in functions and networks relevant to vascular remodelling.

See related Editorial

Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis

  • Pages: 1111-1114
  • First Published: 08 August 2019

This study utilized a combination of non-targeted discovery proteomics with targeted quantitation by mass spectrometry of soluble plasma biomarkers to identify potentially important molecules and pathways in idiopathic pulmonary fibrosis (IPF). Five proteins were identified to be differentially expressed in IPF compared to healthy controls.

See related Editorial

LETTER FROM ASIA-PACIFIC AND BEYOND

Free Access

Letter from Colombia

  • Pages: 1115-1116
  • First Published: 25 July 2019